Martingale Asset Management L P Corcept Therapeutics Inc Transaction History

Martingale Asset Management L P

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$21.1 - $27.46 $642,811 - $836,568	-30,465 Reduced 44.09%	38,625 $972,000
Q4 2023 Feb 12, 2024	SELL	$24.82 - $32.88 $3,971 - $5,260	-160 Reduced 0.23%	69,090 $2.24 Million
Q3 2023 Nov 14, 2023	SELL	$21.97 - $33.8 $208,978 - $321,505	-9,512 Reduced 12.08%	69,250 $1.89 Million
Q2 2023 Aug 11, 2023	BUY	$21.44 - $25.15 $86,038 - $100,926	4,013 Added 5.37%	78,762 $1.75 Million
Q1 2023 May 12, 2023	BUY	$19.2 - $24.47 $20,889 - $26,623	1,088 Added 1.48%	74,749 $1.62 Million
Q4 2022 Feb 13, 2023	BUY	$19.95 - $29.96 $51,929 - $77,985	2,603 Added 3.66%	73,661 $1.5 Million
Q3 2022 Nov 14, 2022	BUY	$24.7 - $29.12 $7,558 - $8,910	306 Added 0.43%	71,058 $1.82 Million
Q2 2022 Aug 11, 2022	BUY	$17.33 - $25.3 $988,295 - $1.44 Million	57,028 Added 415.53%	70,752 $1.68 Million
Q1 2022 May 12, 2022	SELL	$16.53 - $25.21 $880,090 - $1.34 Million	-53,242 Reduced 79.51%	13,724 $309,000
Q4 2021 Feb 11, 2022	BUY	$17.1 - $23.34 $39,535 - $53,962	2,312 Added 3.58%	66,966 $1.33 Million
Q3 2021 Nov 12, 2021	BUY	$19.68 - $22.53 $1.27 Million - $1.46 Million	64,654 New	64,654 $1.27 Million

350

86.1M

1.12M

667K

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $5.92B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Martingale Asset Management L P, based on Form 13F filings with the SEC.

Stay updated on Martingale Asset Management L P with notifications on news.